Overview

The Centers for Disease Control and Prevention (CDC) appointed retsef Levi, a professor at Harvard Medical school and a member of the agency’s Advisory⁣ Committee on Immunization Practices (ACIP), to chair‍ a new workgroup focused on COVID-19.⁣ ⁣ This decision has drawn scrutiny due to Levi’s prior ⁢public statements questioning the safety and efficacy of mRNA vaccines, particularly those manufactured by Moderna⁣ and Pfizer-BioNTech.

Levi’s Previous Statements on mRNA vaccines

Retsef Levi has been a vocal critic of⁤ mRNA vaccines, particularly regarding‍ their potential adverse effects. In May 2023, ‍he testified before Congress, expressing concerns about a potential link between mRNA vaccines and myocarditis, especially in young men [NBC News]. He also⁤ suggested that the CDC and FDA had downplayed potential safety signals. He has repeatedly questioned the benefits⁤ of boosters for healthy ‍young people.

Levi’s concerns extend to the reporting of ⁤adverse events following vaccination. He has argued that current surveillance systems are ⁤inadequate and fail to capture the full extent of potential harms [The Epoch Times]. He has also questioned the transparency of data shared by vaccine manufacturers.

The New CDC Workgroup and its Mandate

The CDC established the new workgroup to provide recommendations on the composition of future COVID-19 ⁢vaccines,⁤ as the virus continues to evolve. The group will also advise on vaccination strategies for⁤ different populations,⁣ considering factors such as ⁣age, underlying health conditions, and prior ‍vaccination status [CDC Press Release]. The workgroup’s recommendations will‍ be presented to the ACIP for consideration and a final vote.

The ⁤CDC stated that ⁤Levi was selected for his expertise in risk assessment⁤ and benefit-risk analysis.